PDS 0202
Alternative Names: Influenza vaccine - PDS Biotechnology; PDS-0202; Universal influenza vaccine - PDS Biotechnology CorporationLatest Information Update: 16 May 2025
At a glance
- Originator PDS Biotechnology Corporation
- Class Influenza virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Influenza virus infections
Most Recent Events
- 16 May 2025 PDS 0202 is still in preclinical trials in Influenza-virus-infections(Prevention) in USA (IM, Injection)
- 28 May 2024 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA (IM, Injection)
- 13 Mar 2024 PDS Biotechnology has patent protection for PDS 02020 composition and use in the US